Coronavirus Infection

9
Pipeline Programs
11
Companies
12
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
3
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
150%
Small Molecule
150%
+ 11 programs with unclassified modality

On Market (2)

Approved therapies currently available

Novartis
ILARISApproved
canakinumab
Novartis
subcutaneous2009
VP
NEREUSApproved
tradipitant
Vanda Pharmaceuticals
oral2025

Competitive Landscape

10 companies ranked by most advanced pipeline stage

VP
Vanda PharmaceuticalsWASHINGTON, DC
2 programs
1
1
TradipitantPhase 31 trial
WGS Analysis of COVID-19 Positive PatientsN/A1 trial
Active Trials
NCT04353401Completed79Est. Mar 2022
NCT04326426Enrolling By Invitation300Est. Aug 2020
Novartis
NovartisBASEL, Switzerland
1 program
1
1
CanakinumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT04510493Completed116Est. Aug 2021
FUJIFILM Pharma
FUJIFILM PharmaMA - Cambridge
1 program
1
FavipiravirPhase 3Small Molecule1 trial
Active Trials
NCT04373733CompletedEst. Jun 2021
Verona Pharma
Verona PharmaUK - London
2 programs
1
Ensifentrine Dose 1Phase 21 trial
Nasopharyngeal swabN/A1 trial
Active Trials
NCT04324866Unknown300Est. Dec 2020
NCT04527471Completed45Est. May 2021
Karyopharm Therapeutics
2 programs
2
SelinexorPhase 21 trial
SelinexorPhase 21 trial
Active Trials
NCT04355676WithdrawnEst. Aug 2020
NCT04349098CompletedEst. Oct 2020
Sanofi
SanofiPARIS, France
1 program
1
Hydroxychloroquine SAR321068Phase 11 trial
Active Trials
NCT04333654Terminated8Est. May 2020
AB
AP BiosciencesTaiwan - Taipei
1 program
Nasal swabN/A1 trial
Active Trials
NCT04366934CompletedEst. Oct 2020
M&
Merck & Co.RAHWAY, NJ
1 program
SARS-CoV-2 Antibody AnalysisN/A1 trial
Active Trials
NCT04596579Completed1,135Est. Jul 2021
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
prayerN/A1 trial
Active Trials
NCT04361838Terminated200Est. Apr 2021
Rhythm Pharmaceuticals
1 program
prayerN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisCanakinumab
FUJIFILM PharmaFavipiravir
Vanda PharmaceuticalsTradipitant
Verona PharmaEnsifentrine Dose 1
Karyopharm TherapeuticsSelinexor
Karyopharm TherapeuticsSelinexor
SanofiHydroxychloroquine SAR321068
Merck & Co.SARS-CoV-2 Antibody Analysis
Vanda PharmaceuticalsWGS Analysis of COVID-19 Positive Patients
City Therapeuticsprayer
AP BiosciencesNasal swab
Verona PharmaNasopharyngeal swab

Clinical Trials (12)

Total enrollment: 2,183 patients across 12 trials

NCT04510493NovartisCanakinumab

Canakinumab in Patients With COVID-19 and Type 2 Diabetes

Start: Oct 2020Est. completion: Aug 2021116 patients
Phase 3Completed
NCT04373733FUJIFILM PharmaFavipiravir

Early Intervention in COVID-19: Favipiravir Verses Standard Care

Start: May 2020Est. completion: Jun 2021
Phase 3Completed
NCT04326426Vanda PharmaceuticalsTradipitant

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Start: Apr 2020Est. completion: Aug 2020300 patients
Phase 3Enrolling By Invitation
NCT04527471Verona PharmaEnsifentrine Dose 1

Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19

Start: Sep 2020Est. completion: May 202145 patients
Phase 2Completed
NCT04355676Karyopharm TherapeuticsSelinexor

Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

Start: Apr 2020Est. completion: Aug 2020
Phase 2Withdrawn
NCT04349098Karyopharm TherapeuticsSelinexor

Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection

Start: Apr 2020Est. completion: Oct 2020
Phase 2Completed
NCT04333654SanofiHydroxychloroquine SAR321068

Hydroxychloroquine in Outpatient Adults With COVID-19

Start: Apr 2020Est. completion: May 20208 patients
Phase 1Terminated
NCT04596579Merck & Co.SARS-CoV-2 Antibody Analysis

SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida

Start: Oct 2020Est. completion: Jul 20211,135 patients
N/ACompleted
NCT04353401Vanda PharmaceuticalsWGS Analysis of COVID-19 Positive Patients

WGS Analysis of COVID-19 Positive Patients

Start: Aug 2020Est. completion: Mar 202279 patients
N/ACompleted
NCT04361838City Therapeuticsprayer

The COVID-19 ICU PRAYER Study

Start: May 2020Est. completion: Apr 2021200 patients
N/ATerminated
NCT04366934AP BiosciencesNasal swab

Study of the Pathogenesis of Olfactory Disorders in COVID-19

Start: May 2020Est. completion: Oct 2020
N/ACompleted
NCT04324866Verona PharmaNasopharyngeal swab

Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy

Start: Apr 2020Est. completion: Dec 2020300 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
11 companies competing in this space